			$ \mathcal{M}$
	Application No.	Applicant(s)	
AL (*	09/830,780	HILLE ET AL.	·
Notice of Allowability	Examiner	Art Unit	
	Manuel Mendez	3763	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.			
1. This communication is responsive to <u>09/13/2004</u> .			
2. The allowed claim(s) is/are <u>19-37,51 and 52.</u>			
3. The drawings filed on are accepted by the Examiner.			
4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a)			
 Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☑ Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date May01 and Jan03 4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material 	5. ☐ Notice of Informal P 6. ☐ Interview Summary Paper No./Mail Dat 8), 7. ☑ Examiner's Amendn 8. ☐ Examiner's Stateme 9. ☐ Other	(PTO-413), e nent/Comment	ŕ

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

The application has been amended as follows:

Claims 38-49 have been cancelled.

The following is an examiner's statement of reasons for allowance:

The prior art of record does not disclose or suggest a process for the administration of a transdermally administrable active compound having a low skin penetration rate, comprising the steps of (a) sticking a skin-adherent patch containing the transdermally administrable active compound onto the skin, (b) treating the skin-adherent patch **solely** with ultrasound during an initial phase, and (c) wearing of the patch during a subsequent long-term phase without additional ultrasonic treatment.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Manuel Mendez whose telephone number is 703-308-2221. The examiner can normally be reached on 0730-1800 hrs.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. Brian Casler can be reached on 703-308-3552. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Manuel Mendez Primary Examiner Art Unit 3763

MM